home / stock / sana / sana news

SANA News and Press, Sana Biotechnology Inc. From 01/03/24

Stock Information
Company Name: Sana Biotechnology Inc.
Stock Symbol: SANA
Market: NASDAQ
Website: sana.com
Menu
SANA SANA Quote SANA Short SANA News SANA Articles SANA Message Board
Get SANA Alerts

News, Short Squeeze, Breakout and More Instantly...
SANA - Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42 nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. P...
SANA - Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development of a HIP-modified allogeneic GPRC5D-directed CAR T cell therapy SEATTLE, Dec. 11, ...

SANA - Sana publishes Phase 1 data for CLL therapy in medical journal

2023-12-01 17:42:04 ET More on Sana Biotechnology Sana Biotechnology: Still Early Days, Lots Of Dilution Ahead Sana Biotech revamps portfolio: to cut 29% of headcount Sana Biotechnology falls after pipeline updates Seeking Alpha’s Quant Rating on Sana ...

SANA - Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at t...
SANA - Sana Biotechnology to Present at November and December 2023 Investor Conferences

SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in November and December. The presentations...

SANA - Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR Newswire Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trilli...

SANA - Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through ...
SANA - DWAC, ROOT and GNFT are among after hour movers

2023-11-13 18:01:34 ET Gainers: Theseus Pharmaceuticals ( THRX ) +35% . GENFIT  ( GNFT ) +15% . Lifeway Foods ( LWAY ) +9% . Digital World Acquisition ( DWACW ) +8% . Digital World Acquisition  ( DWAC ) +5% . Lose...

SANA - Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical data next year SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, I...

SANA - Sana Biotechnology Non-GAAP EPS of -$0.41

2023-11-08 17:45:28 ET Sana Biotechnology press release ( NASDAQ: SANA ): Q3 Non-GAAP EPS of -$0.41. Expect 2024 operating cash burn to be below $200 million, enabling multiple clinical data readouts with our current balance sheet and a cash runway into 2025. For fur...
Previous 10 Next 10